A Study of KCT-0809 in Patients With Dry Eye Syndromes

Kissei

Status and phase: Completed; Phase 2

Conditions: Dry Eye Syndromes

Treatments: Drug: KCT-0809; Drug: Placebo

Study type: Interventional

Funder types: Industry

Identifiers

NCT01211951

KCT1201

Details and patient eligibility

About

The purpose of this study is to evaluate the efficacy and safety of KCT-0809 compared to placebo in patients with dry eye syndromes.

Sex: All

Ages: 20+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Corneal and conjunctival damage
• Insufficiency of lacrimal secretion or tear film instability
• Ocular symptom

Exclusion criteria

• Severe ophthalmic disorder
• Punctual plugs or surgery for occlusion of the lacrimal puncta

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind

---

160 participants in 4 patient groups, including a placebo group

KCT-0809 ophthalmic solution, low dose

Experimental group

Treatment:

Drug: KCT-0809

Drug: KCT-0809

Drug: KCT-0809

KCT-0809 ophthalmic solution, medium dose

Experimental group

Treatment:

Drug: KCT-0809

Drug: KCT-0809

Drug: KCT-0809

KCT-0809 ophthalmic solution, high dose

Experimental group

Treatment:

Drug: KCT-0809

Drug: KCT-0809

Drug: KCT-0809

Placebo

Placebo Comparator group

Treatment:

Drug: Placebo